NRX Pharmaceuticals, Inc. (NRXP) KPIs and segments
Close on Nov 17, 2026Market cap $106.08MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive NRX Pharmaceuticals's business
NRX Pharmaceuticals's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
Therapy($M) | 0.87 | 0.76 | 0.70 | 0.15 | |
Procedures($M) | 0.23 | 0.31 | 0.28 | 0.09 | |
Dura Segment($M) | 0.10 | 0.08 | -0.10 | 0.02 | |
NRx Segment($M) | -6.60 | -4.83 | -4.52 | -4.04 | |
Dura Segment($M) | 0.11 | 0.09 | -0.10 | 0.02 | |
NRx Segment($M) | -16.6 | -1.52 | 0.46 | -5.91 | |
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-14.
See a number that looks wrong?